![Corey S Cutler, MD, MPH, GVHD Expert, with quote: "Your [patients'] goal is to be vigilant when looking for subtle signs and call us as soon as [they] notice a change."](/sites/g/files/hssmmz6261/files/2024-07/mobilehero.webp)
![Corey S Cutler, MD, MPH, GVHD Expert, with quote: "Your [patients'] goal is to be vigilant when looking for subtle signs and call us as soon as [they] notice a change."](/sites/g/files/hssmmz6261/files/2024-07/desktophero.webp)
Developed in partnership with ASTCT, the Day 100 Master Class Series can help you help your patients
See why skin rash is an ideal marker of cGVHD progression3
The Prezerve™ post-transplant symptom tracker app supports early intervention
We all have to become experts specializing in our own form of GVHD.
Brad, a patient with GVHD
Brad, GVHD patient
How do you activate patients to monitor for cGVHD symptoms?
See early signs of cGVHDASTCT=American Society for Transplantation and Cellular Therapy; NIH=National Institutes of Health.
References: 1. Lueck C, Tzalavras A, Wohlfarth P, et al. Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients. Bone Marrow Transplant. 2023;58(3):303-310. 2. Kitko CL, Pidala J, Schoemans HM, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group report. Transplant Cell Ther. 2021;27(7):545-557. 3. Baumrin E, Baker LX, Byrne M, et al. Prognostic value of cutaneous disease severity estimates on survival outcomes in patients with chronic graft-vs-host disease. JAMA Dermatol. 2023;159(4):393-402.